Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 5/20 | 0.54 |
| ▸ | CDK4 | P11802 | 2/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | IGF1R | P08069 | 6/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766261 | 0.87 | CDK2 (0.62) | EGFRERBB2CDK2CDK4CCNE1 | |
| SCHEMBL3727487 | 0.86 | CDK19 (0.69) | EGFRERBB2CDK2IGF1RBRAF | |
| SCHEMBL3765295 | 0.75 | CDK2 (0.56) | EGFRERBB2CDK2CDK4CCNE1 | |
| SCHEMBL3762101 | 0.74 | CDK2 (0.55) | EGFRERBB2CDK2CDK4CCNE1 | |
| SCHEMBL12609813 | 0.74 | RAB9A (0.66) | EGFRERBB2CDK2CDK4IGF1R | |
| SCHEMBL3716771 | 0.73 | CDK19 (0.66) | CDK2CDK4CCNE1IGF1RBRAF | |
| SCHEMBL3764976 | 0.73 | CDK19 (0.76) | EGFRERBB2CDK2CDK4CCNE1 | |
| SCHEMBL3769673 | 0.72 | CDK2 (0.54) | EGFRERBB2CDK2CDK4CCNE1 | |
| SCHEMBL3760568 | 0.71 | CDK2 (0.74) | EGFRCDK2CDK4CCNE1IGF1R | |
| SCHEMBL3306130 | 0.71 | JAK2 (0.46) | MEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435435-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | EGFR 249/4885ERBB2 99/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.